An elevated level of C-reactive protein (CRP), an acute phase protein, is one of many downstream indicators of inflammation. Physiologically, CRP enhances cell-mediated immunity by promoting phagocytosis, accelerating chemotaxis, and activating platelets. The purposes of this article are (1) to review the clinical data implicating serum CRP level as a systemic marker of focal inflammation and (2) to explore serum CRP level as a reflection of the inflammatory component of atherogenesis. Our findings indicate that CRP levels serve as an early marker of the magnitude of inflammation in events as dissimilar as appendicitis and myocardial infarction. The level of circulating CRP correlates with endovascular disease and may serve to identify otherwise asymptomatic patients at sufficient cardiovascular risk to warrant aggressive therapy. Determining whether CRP has a direct pathologic role in the vascular wall itself may have the most clinical relevance.
Systemic inflammation is associated with leukocyte-mediated endothelial dysfunction.1 Proinflammatory cytokines, chemokines, and glucocorticoid hormones are elaborated and stimulate hepatocytes to synthesize a wide array of acute phase proteins (Figure 1).2,3 A dominant acute phase protein in mammals, C-reactive protein (CRP) is a 206–amino acid pentameric polypeptide.4 Originally isolated from the serum of patients with pneumonia, it has a high binding affinity for pneumococcal C polysaccharide.5 Although CRP level correlated with infection, this qualitative relationship did not predict disease severity. By the 1980s a sensitive and specific quantitative assay for CRP was commercially available. Subsequently, mounting clinical evidence suggests an early quantitative correlation between plasma CRP levels and several inflammatory states.
Rapidly synthesized acute phase proteins support host defenses by neutralizing offending antigens, controlling tissue damage, and promoting tissue repair. C-reactive protein acts as an opsonin for invading bacteria and circulating immune complexes.6 C-reactive protein may also activate the complement cascade and scavenge chromatin after cellular necrosis.7 These functions promote phagocytosis, accelerate chemotaxis, and activate circulating platelets. Ultimately, CRP accelerates the clearance of microbial debris from the circulation and enhances cell-mediated immunity. Plasma levels of CRP can be detected as early as 4 hours after injury and peak (1000-fold increase) between 24 and 72 hours after injury.8,9 The purposes of this article are (1) to review the clinical data implicating CRP level as a systemic marker of focal inflammation, (2) to explore CRP level as an indicator of the endovascular inflammation that leads to atherogenesis, and (3) to examine anti-inflammatory strategies against atherosclerosis.
C-reactive protein and surgical disease
C-reactive protein is a reliable early indicator of inflammation or injury. Mustard and colleagues10 documented that serial postoperative CRP levels could predict septic complications before their clinical manifestation. Indeed, serial CRP levels in trauma patients aid in the discrimination of bacterial sepsis from noninfectious systemic inflammatory response syndrome.11 A cutoff value of 17 mg/dL or more for CRP gives a sensitivity of 74% and a specificity of 75% in predicting the presence of infection. Level of CRP also predicts the severity of acute cholecystitis (>10 mg/dL is strongly related to tissue necrosis)12 and serves as an accurate marker in risk assessment for postoperative amputation in patients undergoing femoropopliteal bypass.13
If CRP level indicates local infection, can CRP levels enhance the precision of the difficult diagnosis of common entities such as acute appendicitis? A large retrospective study has documented that the sensitivity of CRP in these patients is greater than 90%.14 Furthermore, the negative appendectomy rate is reduced by approximately 8% if surgery is canceled in patients with CRP levels and white blood cell counts within the reference range.15 Eriksson and colleagues16 prospectively measured serial CRP and white blood cell levels in patients with suspected appendicitis. Levels were determined every 4 hours following admission and the operating surgeon was blinded to all but initial values. The sensitivity of CRP level in predicting appendicitis was 60% on admission and increased to 100% by the fourth draw. Conversely, white blood cell counts exhibited a sensitivity of 95% on admission, but dropped to 75% by the fourth draw. Multiple studies17,18 confirm that an elevated CRP level serves as a systemic marker of focal inflammation and infection.
Inflammation and cardiovascular disease
Accumulating data pathologically link atherosclerosis and the inflammatory response to vascular injury.19,20 Luminal injury associated with hyperlipidemia, hypertension, and/or angioplasty results in endothelial cell dysfunction, adhesion molecule expression, and inflammatory cell infiltration.1 The autocrine and paracrine effects of cytokines and chemokines promote oxidized lipid deposition with vascular smooth muscle cell proliferation and migration. This chronic vascular wall inflammation leads not only to progressive luminal stenosis but also to plaque instability.21 Thus, a systemic marker that identifies the patient with "smoldering" vascular inflammation is intuitively attractive.
Several prospective studies have demonstrated a direct correlation between acute myocardial infarction (MI) rise in CRP, postinfarction adverse events,22,23 and subsequent infarct size24 (Table 1). The European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Study also reported elevated CRP levels in more than 2000 outpatients with stable and unstable angina.25 This study identified a 2-fold increase in the risk of MI and sudden cardiac death in any patient with a CRP level greater than 0.36 mg/dL. Toss and colleagues26 observed more than 900 patients with unstable angina or non–Q-wave infarction and reported a positive correlation between elevated CRP level and mortality.26 Thus, an elevated CRP level does appear to correlate with incidence of acute coronary syndromes.
Elevated CRP Level as an Indicator of Endovascular Instability
Elevated CRP level is also associated with an increased risk of both 30-day mortality and MI following angioplasty.40 Elevated preangioplasty CRP levels of greater than 0.3 mg/dL predicted an increased rate of procedural and in-hospital complications.41 At 1-year follow-up, clinical restenosis developed in 63% of patients with high preangioplasty CRP levels vs only 27% of those with values in the reference range. Milazzo and colleagues42 reported a similar trend in 86 patients who underwent elective coronary artery bypass grafting. Twenty-five percent of patients with initial CRP values of 0.3 mg/dL or higher experienced postoperative ischemic events, vs only 4% of those with values in the reference range.
Direct CRP-Mediated Vascular Disease
The evolving concept of CRP acting as a direct pathologic mediator in vascular remodeling may ultimately provide the most clinical relevance. C-reactive protein has been localized to the neointima of atherosclerotic plaque43 and activates complement in early lesions.44 Although hepatic production has classically been identified as the primary source, Yasojima and colleagues45 recently demonstrated that CRP is also expressed by vascular smooth muscle cells and macrophages resident in atherosclerotic lesions. Furthermore, CRP induces endothelial cell expression of adhesion molecules and monocyte chemoattractant protein 1.46 Recently, Fu and Borensztajn47 demonstrated that CRP promotes the aggregation of low-density lipoprotein, thus contributing to foam-cell formation within atherosclerotic lesions. This local influence, coupled with the well-documented proinflammatory effects of CRP on monocytes and macrophages, supports a direct deleterious role of CRP in the vascular wall itself.48 Although systemic markers of focal inflammatory processes are becoming increasingly useful for risk stratification in cardiovascular disease, targeting specific pathologic culprits within the inflammatory cascade may permit a direct therapeutic benefit.
Elevated CRP Level in Asymptomatic Patients
Several small cross-sectional and case-control studies have even suggested that CRP levels may be predictive of cardiovascular disease in asymptomatic patients.36-39 The Multiple Risk Factor Intervention Trial (MRFIT)27 was the first prospective study to report the relationship between CRP and coronary disease in asymptomatic, but high-risk, men. In this 17-year study, increased CRP levels directly correlated with mortality. Results from the Physicians' Health Study,28 a randomized, double-blind trial of treatment with aspirin and beta carotene in the prevention of cardiovascular disease, also documented the link between CRP levels and risk of MI and stroke in healthy men. Interestingly, when smoldering endovascular inflammation is suppressed with aspirin therapy, risk reduction is directly related to CRP levels. The Monitoring Trends and Determinants in Cardiovascular Disease (MONICA)31 study measured CRP levels in healthy men with an 8-year follow-up. This study also identified an association between elevated CRP levels and the risk of both fatal and nonfatal MI in 936 patients. Recently, the Speedwell Prospective Study34 also correlated systemic inflammation and ischemic heart disease and reported a decrease in CRP level with smoking cessation in more than 1000 men. High CRP levels have also proven to be predictive of adverse cardiovascular events in healthy women30,33 and the elderly.32 Not surprisingly, a positive association has been found between CRP level and the risk of developing peripheral arterial disease.29,35
Anti-inflammatory therapy
Antiplatelet and/or lipid-lowering agents have traditionally been used for the prevention of acute cardiovascular events.49 An evolving pharmacologic paradigm links these drugs and serum CRP levels. The Nurses' Health Study50 analyzed the incidence of coronary events in more than 80 000 women who were taking aspirin regularly. Overall, 1 to 6 aspirin tablets per week resulted in a decrease in nonfatal MI and fatal coronary disease. These results have been corroborated in several large, randomized studies.51-55 Ridker and colleagues28 documented that the benefit of aspirin therapy was greatest in healthy men with the highest CRP levels. Although the risk reduction of MI in this group was 55.7%, the beneficial effect was reduced as CRP levels decreased. These data emphasize the inflammatory component of cardiovascular disease and suggest that aspirin therapy may directly affect endovascular dysfunction, as indicated by CRP production. Furthermore, CRP level may serve as an indicator of patients at risk and as a practical marker of the efficacy of the preventive strategy.
Several large trials56-58 have linked the use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) to the attenuation of serum CRP levels. Recently, the Air Force/Texas Coronary Artery Prevention Study (AFCAPS/TexCAPS) investigators reported the effects of lovastatin on CRP levels in patients with and without hyperlipidemia.59 Apart from its lipid-lowering effects, lovastatin reduced CRP levels by 14.8%. Lovastatin was effective in preventing coronary events in patients with elevated cholesterol levels and was also effective in patients with low cholesterol and high CRP levels. Thus, not only does CRP level reliably reflect inflammation, but its suppression is associated with a reduction in adverse cardiovascular events.
Although the effects of these prophylactic agents on CRP level are promising, there are concerns regarding widespread use of aspirin for primary prevention. A recent review of the cumulative experience with aspirin summarizes the results of 5 randomized studies.60 With the exception of one British study,51 4 trials documented a reduction in the rate of MI in patients treated with aspirin.52-55 However, a meta-analysis evaluating these trials reported a 69% increase in bleeding complications.61 Thus, aspirin prophylaxis can be justified only in patients who are at increased risk for cardiovascular events. Sanmuganathan and colleagues61 recommend preventative aspirin therapy only in patients with a coronary event risk of at least 1.5% per year.
In addition to nausea, abdominal discomfort, and headaches, all statins pose the risk of myopathy and fatal rhabdomyolysis.62 The mechanism of skeletal muscle toxic effects is likely due to inhibition of drug metabolism and subsequent increase in plasma statin concentrations. In addition, statins interact with a wide array of drugs, including immunosuppressants, azole antifungals, coumarin anticoagulants, and calcium channel antagonists. Despite their widespread use in cardiovascular patients, the precise mechanism by which aspirin and statins reduce CRP levels is unknown. Although the anti-inflammatory effects of each agent are well documented, it is unknown whether these drugs mediate CRP expression directly or whether this effect is secondary to a decrease in well-described inflammatory promoters of CRP production.
While the prognostic role of CRP levels in numerous surgical diseases is still being defined, its value in risk stratification of cardiovascular patients is increasingly convincing. Recently, Ridker and colleagues63 reported that serum CRP levels might be more predictive than low-density lipoprotein cholesterol levels of adverse cardiovascular events. More than 75% of patients with elevated CRP levels experienced a major cardiac event despite low-density lipoprotein cholesterol levels that were lower than the threshold recommended for pharmacologic intervention. The implications of these observations are significant in that patients not receiving statins and other risk-factor modifications may, in fact, require aggressive therapy.
Corresponding author and reprints: Michael A. Zimmerman, MD, Department of Surgery, Campus Box C-320, University of Colorado Health Sciences Center, 4200 East Ninth Ave, Denver, CO 80262 (e-mail: michael.zimmerman@UCHSC.edu).
This study was supported by grants GM49222 and GM08315 from the National Institutes of Health, Bethesda, Md (Dr Harken).
1.Higashi
YSasaki
SNakagawa
KMatsuura
HOshima
TChayama
K Endothelial function and oxidative stress in renovascular hypertension.
N Engl J Med. 2002;3461954- 1962
Google ScholarCrossref 2.Gambino
R C-reactive protein—undervalued, underutilized.
Clin Chem. 1997;432017- 2018
Google Scholar 3.Baumann
HJahreis
GPMorella
KK
et al. Transcriptional regulation through cytokine and glucocorticoid response elements of rat acute phase plasma protein genes by C/EBP and JunB.
J Biol Chem. 1991;26620390- 20399
Google Scholar 5.Tillet
WSFrancis
T
Jr Serologic reactions in pneumonia with a nonprotein fraction from
Pneumococcus. J Exp Med. 1930;52561- 571
Google ScholarCrossref 6.Babu
ED Would measurement of C-reactive protein reduce the rate of negative exploration for acute appendicitis?
J R Coll Surg Edinb. 2000;45202- 203
Google Scholar 7.Robey
FAJones
KDTanaka
TLiu
TY Binding of C-reactive protein to chromatin and nucleosome core particles: a possible physiological role of C-reactive protein.
J Biol Chem. 1984;2597311- 7316
Google Scholar 8.Foglar
CLindsey
RW C-reactive protein in orthopedics.
Orthopedics. 1998;21687- 691
Google Scholar 9.Steel
DMWhitehead
AS The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein.
Immunol Today. 1994;1581- 88
Google ScholarCrossref 10.Mustard
RA
JrBohnen
JMHaseeb
SKasina
R C-reactive protein levels predict postoperative septic complications.
Arch Surg. 1987;12269- 73
Google ScholarCrossref 11.Miller
PRMunn
DDMeredith
JWChang
MC Systemic inflammatory response syndrome in the trauma intensive care unit: who is infected?
J Trauma. 1999;471004- 1008
Google ScholarCrossref 12.Schafer
MKrahenbuhl
LBuchler
MW Predictive factors for the type of surgery in acute cholecystitis.
Am J Surg. 2001;182291- 297
Google ScholarCrossref 13.Matzke
SBiancari
FIhlberg
L
et al. Increased preoperative C-reactive protein level as a prognostic factor for postoperative amputation after femoropopliteal bypass surgery for CLI.
Ann Chir Gynaecol. 2001;9019- 22
Google Scholar 14.Paajanen
HMansikka
ALaato
MKettunen
JKostiainen
S Are serum inflammatory markers age dependent in acute appendicitis?
J Am Coll Surg. 1997;184303- 308
Google Scholar 15.Eriksson
SGranstrom
LBark
S Laboratory tests in patients with suspected acute appendicitis.
Acta Chir Scand. 1989;155117- 120
Google Scholar 16.Eriksson
SGranstrom
LCarlstrom
A The diagnostic value of repetitive preoperative analyses of C-reactive protein and total leucocyte count in patients with suspected acute appendicitis.
Scand J Gastroenterol. 1994;291145- 1149
Google ScholarCrossref 17.Andersson
REHugander
APGhazi
SH
et al. Diagnostic value of disease history, clinical presentation, and inflammatory parameters of appendicitis.
World J Surg. 1999;23133- 140
Google ScholarCrossref 18.Gronroos
JMGronroos
P Leucocyte count and C-reactive protein in the diagnosis of acute appendicitis.
Br J Surg. 1999;86501- 504
Google ScholarCrossref 20.Selzman
CHMiller
SAHarken
AH Therapeutic implications of inflammation in atherosclerotic cardiovascular disease.
Ann Thorac Surg. 2001;712066- 2074
Google ScholarCrossref 21.Plutzky
J Inflammatory pathways in atherosclerosis and acute coronary syndromes.
Am J Cardiol. 2001;8810K- 15K
Google ScholarCrossref 22.Berk
BCWeintraub
WSAlexander
RW Elevation of C-reactive protein in "active" coronary artery disease.
Am J Cardiol. 1990;65168- 172
Google ScholarCrossref 23.Liuzzo
GBiasucci
LMGallimore
JR
et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina.
N Engl J Med. 1994;331417- 424
Google ScholarCrossref 24.Pietila
KHarmoinen
AHermens
WSimoons
MLVan de Werf
FVerstraete
M Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy.
Eur Heart J. 1993;14915- 919
Google ScholarCrossref 25.Haverkate
FThompson
SGPyke
SDGallimore
JRPepys
MBEuropean Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group, Production of C-reactive protein and risk of coronary events in stable and unstable angina.
Lancet. 1997;349462- 466
Google ScholarCrossref 26.Toss
HLindahl
BSiegbahn
AWallentin
LFRISC Study Group (Fragmin during Instability in Coronary Artery Disease), Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease.
Circulation. 1997;964204- 4210
Google ScholarCrossref 27.Kuller
LHTracy
RPShaten
JMeilahn
EN Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial.
Am J Epidemiol. 1996;144537- 547
Google ScholarCrossref 28.Ridker
PMCushman
MStampfer
MJTracy
RPHennekens
CH Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
N Engl J Med. 1997;336973- 979
Google ScholarCrossref 29.Ridker
PMCushman
MStampfer
MJTracy
RPHennekens
CH Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.
Circulation. 1998;97425- 428
Google ScholarCrossref 30.Ridker
PMBuring
JEShih
JMatias
MHennekens
CH Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
Circulation. 1998;98731- 733
Google ScholarCrossref 31.Koenig
WSund
MFrohlich
M
et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
Circulation. 1999;99237- 242
Google ScholarCrossref 32.Harris
TBFerrucci
LTracy
RP
et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.
Am J Med. 1999;106506- 512
Google ScholarCrossref 33.Ridker
PMHennekens
CHBuring
JERifai
N C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.
N Engl J Med. 2000;342836- 843
Google ScholarCrossref 34.Lowe
GDYarnell
JWRumley
ABainton
DSweetnam
PM C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis?
Arterioscler Thromb Vasc Biol. 2001;21603- 610
Google ScholarCrossref 35.Ridker
PMStampfer
MJRifai
N Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease.
JAMA. 2001;2852481- 2485
Google ScholarCrossref 36.Mendall
MAPatel
PBallam
LStrachan
DNorthfield
TC C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study.
BMJ. 1996;3121061- 1065
Google ScholarCrossref 37.Tracy
RPLemaitre
RNPsaty
BM
et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project.
Arterioscler Thromb Vasc Biol. 1997;171121- 1127
Google ScholarCrossref 38.Danesh
JWhincup
PWalker
M
et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.
BMJ. 2000;321199- 204
Google ScholarCrossref 39.Roivainen
MViik-Kajander
MPalosuo
T
et al. Infections, inflammation, and the risk of coronary heart disease.
Circulation. 2000;101252- 257
Google ScholarCrossref 40.Chew
DPBhatt
DLRobbins
MA
et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention.
Circulation. 2001;104992- 997
Google ScholarCrossref 41.Buffon
ALiuzzo
GBiasucci
LM
et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.
J Am Coll Cardiol. 1999;341512- 1521
Google ScholarCrossref 42.Milazzo
DBiasucci
LMLuciani
N
et al. Elevated levels of C-reactive protein before coronary artery bypass grafting predict recurrence of ischemic events.
Am J Cardiol. 1999;84459- 461
Google ScholarCrossref 43.Torzewski
MRist
CMortensen
RF
et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor–dependent monocyte recruitment in atherogenesis.
Arterioscler Thromb Vasc Biol. 2000;202094- 2099
Google ScholarCrossref 44.Torzewski
JTorzewski
MBowyer
DE
et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries.
Arterioscler Thromb Vasc Biol. 1998;181386- 1392
Google ScholarCrossref 45.Yasojima
KSchwab
CMcGeer
EGMcGeer
PL Generation of C-reactive protein and complement components in atherosclerotic plaques.
Am J Pathol. 2001;1581039- 1051
Google ScholarCrossref 46.Pasceri
VCheng
JSWillerson
JTYeh
ETChang
J Modulation of C-reactive protein–mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.
Circulation. 2001;1032531- 2534
Google ScholarCrossref 47.Fu
TBorensztajn
J Macrophage uptake of LDL bound to aggregated C-reactive protein: possible mechanism of foam cell formation in atherosclerotic lesions.
Biochem J. 2002;366195- 201
Google Scholar 49.Selzman
CH Current approaches to therapy for vascular injury.
Expert Opin Pharmacother. 2001;2753- 764
Google ScholarCrossref 50.Manson
JEStampfer
MJColditz
GA
et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
JAMA. 1991;266521- 527
Google ScholarCrossref 51.Peto
RGray
RCollins
R
et al. Randomised trial of prophylactic daily aspirin in British male doctors.
Br Med J. 1988;296313- 316
Google ScholarCrossref 52.Hansson
LZanchetti
ACarruthers
SG
et al. HOT Study Group, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet. 1998;3511755- 1762
Google ScholarCrossref 53.de Gaetano
GCollaborative Group of the Primary Prevention Project, Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.
Lancet. 2001;35789- 95
Google ScholarCrossref 54.The Medical Research Council's General Practice Research Framework, Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.
Lancet. 1998;351233- 241
Google ScholarCrossref 55.Steering Committee of the Physicians' Health Study Research Group, Final report on the aspirin component of the ongoing Physicians' Health Study.
N Engl J Med. 1989;321129- 135
Google ScholarCrossref 56.Ridker
PMRifai
NLowenthal
SP Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
Circulation. 2001;1031191- 1193
Google ScholarCrossref 57.Ridker
PMRifai
NPfeffer
MASacks
FBraunwald
ECholesterol and Recurrent Events (CARE) Investigators, Long-term effects of pravastatin on plasma concentration of C-reactive protein.
Circulation. 1999;100230- 235
Google ScholarCrossref 58.Albert
MADanielson
ERifai
NRidker
PM Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study.
JAMA. 2001;28664- 70
Google ScholarCrossref 59.Ridker
PMRifai
NClearfield
M
et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
N Engl J Med. 2001;3441959- 1965
Google ScholarCrossref 60.Lauer
MS Clinical practice: aspirin for primary prevention of coronary events.
N Engl J Med. 2002;3461468- 1474
Google ScholarCrossref 61.Sanmuganathan
PSGhahramani
PJackson
PRWallis
EJRamsay
LE Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
Heart. 2001;85265- 271
Google ScholarCrossref 62.Igel
MSudhop
Tvon Bergmann
K Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A–reductase inhibitors (statins).
Eur J Clin Pharmacol. 2001;57357- 364
Google ScholarCrossref 63.Ridker
PMRifai
NRose
LBuring
JECook
NR Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.
N Engl J Med. 2002;3471557- 1565
Google ScholarCrossref